American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. - Wikidata - awgldk - TriplyDB

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

http://www.wikidata.org/entity/Q36485520

about

Drugs for the treatment of nausea and vomiting in adults in the emergency department setting Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adults Drugs for the treatment of nausea and vomiting in adult patients in the emergency department setting Serotonin receptor antagonists for highly emetogenic chemotherapy in adults Serotonin receptor antagonists for highly emetogenic chemotherapy in adults Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adults Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients The therapeutic potential of cannabis and cannabinoids Chemotherapy-and cancer-related nausea and vomiting Palonosetron (Aloxi): a second-generation 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting The 5-HT3 receptor as a therapeutic target Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adults Prophylactic Management of Radiation-Induced Nausea and Vomiting Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting Food restriction, refeeding, and gastric fill fail to affect emesis in musk shrews.Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).Synthetic and natural antioxidants attenuate cisplatin-induced vomiting Can administrative data be used to measure chemotherapy side effects?Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.Antiemetics: American Society of Clinical Oncology clinical practice guideline update.Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.Update and new trends in antiemetic therapy: the continuing need for novel therapies.Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting Evaluating the various phases of cisplatin-induced emesis in rats.Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.

P2860

Q24186973-B586DE5A-2E42-41CF-A772-C8A58835EDC5 Q24200792-3634EA1D-6EE4-49FE-91AF-DEEEB2681226 Q24201285-EF337864-7213-40DA-A08D-6849E7C55D58 Q24202033-CFD83779-DDF7-4F47-B5E5-C902DBB2DCA0 Q24240511-3DE7364A-35BA-4098-BA34-7F6CC25277C8 Q24243745-DC88F0C1-E0DB-4C2D-8690-656EC26A9BBB Q24245485-67B34421-E610-4C44-8036-D088F17BF617 Q24600806-859107B5-B70B-46D0-9F02-27CF31B35FAB Q24644831-877136F7-F059-4941-AF8A-0525D356B65B Q24669786-9A242324-7BA4-45C0-B923-4A30AD8873D2 Q24681066-E9BD2F90-3BEB-4011-A393-8D23F0A39B0D Q26472106-281B97B5-3B1D-4250-ADC0-BB00E645C02C Q26783184-ADB4352E-FCC9-4112-A39C-197A994289F6 Q28081186-4FDC6E5B-A441-4181-A3AA-2E9D75BDA50F Q28258863-01CE9D34-A273-42DD-A2EB-C7A9A8D509CC Q30433586-C4863FF1-60FD-4E83-95EC-9E505B927033 Q30436557-02AA9B7D-DE25-4DD2-8ACE-5752E5D89EDA Q30834914-A6FD9387-1C91-4BA9-BD01-498391A377DD Q30877306-E6D796E4-3FD8-41E1-B3B2-5D3D0F94C528 Q30973575-CBE6E69F-13C8-470E-8C49-9D16AB369120 Q33158720-40E618D7-1C42-4BB8-B9CA-CE4DAF007447 Q33286793-B058D8D7-7C58-4E9A-9FC1-C7EEFB67F4BF Q33400678-553F48CA-CCD5-4113-B159-6AC118FA9685 Q33406206-9D928020-6B37-4DAA-9CAD-7A4934DE5711 Q33407021-2B839A9F-0FE0-460B-A901-E18874C4F0C2 Q33543954-859D920E-6F1E-4C38-B8B1-D38465A0D2FF Q33584510-C4352BF2-015B-4763-B5FD-02A69D62E5A3 Q33834310-AA75628B-966E-4E7D-8CFC-74AB3673057B Q33992722-0EDD191B-A26B-4E50-9B7E-651E6C2806AC Q34013540-2BF2E80B-40AB-4D4D-A4CB-F26489D2FF63 Q34030613-46A4BB3C-AD18-4B55-B200-9B04FAA45099 Q34038796-CDBFB85E-72F9-4A55-9577-9572576266F3 Q34095827-E875B684-FBB1-4C5D-AC97-85EB3F817258 Q34121232-176CA374-E5A7-4562-ADB5-F8047A69A210 Q34124711-7650C661-D77A-463D-9E49-34EC854E79CE Q34130599-8F086CD7-2C01-488D-B9F5-BB6EA9033795 Q34143667-552A63D8-B21B-4D14-95CF-050338101DE4 Q34239808-652FB9A2-D602-4F38-9CAB-9243973BA9FA Q34293135-0B1F567E-43B5-4547-BDB8-638FDCD9D2C3 Q34327488-7C358A49-C166-40F3-A6C6-AF960B82AE9D

P2860

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

http://www.wikidata.org/entity/Q36485520

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

@ast

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

@en

type

label

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

@ast

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

@en

prefLabel

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

@ast

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

@en

P1433

Q36485520-E2300B58-DBDE-4A7F-869A-A516F665028D

P1476

Q36485520-BD899F8C-ACE2-4786-A064-94D433C2A6B7

P2093

Q36485520-12DBCBF1-6EBC-4810-BBC0-22607BC13406

Q36485520-4CDA9732-43AE-4543-BB85-A657D709F9F4

Q36485520-5A673A5B-8F65-4B8E-BC90-B27DA3EE72CD

Q36485520-5F40FE26-AFDA-4E0A-99B0-59C3C81BB822

Q36485520-6B512B24-BA8F-45D8-93F3-C9D4FE9B1B63

Q36485520-700FFDAC-A4B2-40E9-8137-95CF6F64A29E

Q36485520-8615FD4D-E867-4614-9A07-677ABF864044

Q36485520-8CF47AA7-5A4A-4F18-BB25-FBCD87F48020

Q36485520-8D4E92A4-5EB9-41E5-AF41-FAFAC72087DF

Q36485520-BCDA88E4-4F31-4F4C-A340-AF0BE7A0054F

P304

Q36485520-23115784-75D5-411C-AF67-71CE27CB3AA3

P31

Q36485520-ADEF3C1E-81B5-4B20-BBE5-CAA7392040F8

P356

Q36485520-CB575D34-DB8E-4979-B857-06DD17F85875

P407

Q36485520-32E0C31A-1DF5-41E6-A7EE-1705D2622080

P433

Q36485520-82277F01-A64A-4803-8D5F-F491AEFE5EA0

P478

Q36485520-8F8C8B8D-D2C5-4F20-BA5A-09E9D316C1C4

P50

Q36485520-58F437BD-8A08-4111-8ED5-3146D3956C83

P577

Q36485520-2CCD7A4F-0833-43B0-9029-A6CE7B28BAC4

P698

Q36485520-A5401002-6256-4267-BE82-C5ABC336FDE3

P356

JCO.2006.06.9591

P1433

Journal of Clinical Oncology

P1476

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

@en

P2093

Gary R Morrow

http://www.w3.org/2001/XMLSchema#string

James M Koeller

http://www.w3.org/2001/XMLSchema#string

Lawrence W Chinnery

http://www.w3.org/2001/XMLSchema#string

Mark G Kris

http://www.w3.org/2001/XMLSchema#string

Mark R Somerfield

http://www.w3.org/2001/XMLSchema#string

Maurice J Chesney

http://www.w3.org/2001/XMLSchema#string

Paul J Hesketh

http://www.w3.org/2001/XMLSchema#string

Petra Feyer

http://www.w3.org/2001/XMLSchema#string

Rebecca Clark-Snow

http://www.w3.org/2001/XMLSchema#string

Richard J Gralla

http://www.w3.org/2001/XMLSchema#string

P304

2932-2947

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.06.9591

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

American Society of Clinical Oncology

P577

2006-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16717289

http://www.w3.org/2001/XMLSchema#string